Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 ... - PR Newswire
Innovent Biologics presents updated Phase 2 trial results of Dupert® (fulzerasib), a KRAS G12C inhibitor for advanced NSCLC at WCLC 2024. Fulzerasib showed 49.1% ORR and 90.5% DCR, with a median PFS of 9.7 months. It was well-tolerated, with no additional safety signals. Dupert® was approved by NMPA in August 2024 for KRAS G12C mutated NSCLC patients.
Related Clinical Trials
Reference News
Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 ... - PR Newswire
Innovent Biologics presents updated Phase 2 trial results of Dupert® (fulzerasib), a KRAS G12C inhibitor for advanced NSCLC at WCLC 2024. Fulzerasib showed 49.1% ORR and 90.5% DCR, with a median PFS of 9.7 months. It was well-tolerated, with no additional safety signals. Dupert® was approved by NMPA in August 2024 for KRAS G12C mutated NSCLC patients.